Related Experiment Video
Updated: Sep 10, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS)
Venkata Madhavi Latha Telagarapu1,2,3,4, Priyanka Devi Nallamothu5, Venkata Nikhila Telagarapu6
1Internal Medicine, Private Practice, New York, USA.
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that significantly affects both obese and non-obese women of reproductive age. Besides genetic and epigenetic factors, obesity and insulin resistance (IR) play a key role in the pathogenesis of PCOS, contributing to its endocrine, reproductive, and metabolic manifestations. Even though metformin remains a well-established treatment in the management of PCOS, emerging therapies and integrative approaches warrant comparison. This narrative review aims to understand the pathophysiology of PCOS and compare the role of metformin with that of new emerging therapies, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, oral contraceptive pills (OCPs), inositol supplements, and lifestyle modifications, thereby empowering clinicians to provide personalized medicine based on each patient's unique presentation. This review explores the safety, efficacy, and clinical outcomes of these interventions on weight reduction, hormonal balance, menstrual regularity, and metabolic outcomes in both obese and non-obese women with PCOS.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
Oogenesis

